Data for ST003256   

(Analysis AN005338): Average values per metabolite and experimental factor (Units:absolute intensities)

Metabolite structureAll dataF1F2F3F4F5F6F7F8F9F10F11F12F13F14F15F16F17F18
PC 16:0/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.06 0.10 0.10 0.06 0.10 0.18 0.13 0.08 0.06 0.19 0.14
PC 16:0/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.03 0.04 0.02 0.01 0.01 0.02 0.02
PC 16:0/20:4;O3
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.02 0.00 0.01 0.03 0.02
PC 16:0/22:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00
PC 18:0/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.06 0.09 0.09 0.09 0.10 0.17 0.14 0.10 0.06 0.20 0.14
PC 18:0/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.03 0.02 0.02 0.05 0.05 0.03 0.02 0.02 0.04 0.02
PC 18:0/20:4;O3
0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.00
PC 18:0/22:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.08 0.11 0.09 0.04 0.08 0.08 0.07 0.05 0.04 0.10 0.06
PC 18:1/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.06 0.08 0.08 0.05 0.11 0.20 0.16 0.06 0.06 0.18 0.16
PC 18:1/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.03 0.03 0.02 0.01 0.01 0.03 0.01
PE 16:0/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 16:0/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 16:0/20:4;O3
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 16:0/22:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 16:0/22:4;O2*
0.00 - - 0.00 - 0.00 0.00 - 0.00 - - - - - - 0.00 - 0.00
PE 16:0/22:4;O3*
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:0/20:4;O
0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01
PE 18:0/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:0/20:4;O3
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:0/22:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:0/22:4;O2*
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:0/22:4;O3*
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:1/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:1/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PE 18:1/20:4;O3
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PI 16:0/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 16:0/20:4;O2
0.00 0.00 0.00 0.00 0.00 - - 0.00 - - - 0.00 - - - - - -
PI 16:0/20:4;O3
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 16:0/22:4;O
- 0.00 - 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:0/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:0/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:0/20:4;O3
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:0/22:4;O
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:0/22:4;O2*
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:0/22:4;O3*
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:1/20:4;O
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:1/20:4;O2
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -
PI 18:1/20:4;O3
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 - - - 0.00 - - - 0.00 - -

Factors:

F1Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:DMSO | Treatment Time:2 h
F2Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (10 µM) | Treatment Time:2 h
F3Sample source:Breast cancer cells | Genotype:shCtrl | Treatment:RSL3 (1 µM) | Treatment Time:2 h
F4Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:DMSO | Treatment Time:2 h
F5Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (10 µM) | Treatment Time:2 h
F6Sample source:Breast cancer cells | Genotype:shZeb1 | Treatment:RSL3 (1 µM) | Treatment Time:2 h
F7Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:24 h
F8Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:2 h
F9Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:4 h
F10Sample source:Breast cancer cells | Genotype:WT | Treatment:DMSO | Treatment Time:6 h
F11Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:24 h
F12Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:2 h
F13Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:4 h
F14Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (10 µM) | Treatment Time:6 h
F15Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:24 h
F16Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:2 h
F17Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:4 h
F18Sample source:Breast cancer cells | Genotype:WT | Treatment:RSL3 (1 µM) | Treatment Time:6 h
  logo